Literature DB >> 7657845

Surrogate biochemical markers: precise measurement for strategic drug and biologics development.

J W Lee1, J D Hulse, W A Colburn.   

Abstract

More efficient drug and biologics development is necessary for future success of pharmaceutical and biotechnology companies. One way to achieve this objective is to use rationally selected surrogate markers to improve the early decision-making process. Using typical clinical chemistry methods to measure biochemical markers may not ensure adequate precision and reproducibility. In contrast, using analytical methods that meet good laboratory practices along with rational selection and validation of biochemical markers can give those who use them a competitive advantage over those who do not by providing meaningful data for earlier decision making.

Mesh:

Substances:

Year:  1995        PMID: 7657845     DOI: 10.1002/j.1552-4604.1995.tb04089.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

1.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 2.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Validation of analytic methods for biomarkers used in drug development.

Authors:  Cindy H Chau; Olivier Rixe; Howard McLeod; William D Figg
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.